Galderma presents three-year Nemluvio data in atopic dermatitis
AI Summary- Galderma presented new three-year ARCADIA extension data for Nemluvio.
- Nemluvio was well-tolerated and associated with improvements in lesions, itch, sleep and quality of life.
- Adults and adolescents with moderate-to-severe atopic dermatitis were included in the study.